Keywords: Ambrx, Merck & Co, Technology, Biologic drug conjugates, Collaboration

Ambrx signs up to $300 million deal with Merck & Co

Article | 19 June 2012

Print This

Privately-held California-based Ambrx has entered into a collaboration with US drug giant Merck & Co (NYSE: MRK) to design and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in